Edgar Filing: BIOGEN IDEC INC. - Form 4

BIOGEN IDEC INC. Form 4 July 18, 2013					
FORM A	OMB APPROVAL				
UNITED STATE	CS SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION OMB Number: 3235-0287			
Subject to Section 16. Form 4 or Form 5 obligations may continue. Filed pursuant to Section 17(a) of the	DF CHANGES IN BENEFICIAL OW SECURITIES D Section 16(a) of the Securities Exchange Public Utility Holding Company Act of n) of the Investment Company Act of 19	YNERSHIP OFExpires:January 31, 2005Estimated average burden hours per responseEstimated average burden hours per response0.5			
See Instruction 30(f 1(b).	i) of the investment company ret of 19				
(Print or Type Responses)					
1. Name and Address of Reporting Person * SCANGOS GEORGE A	2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]	5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle)	3. Date of Earliest Transaction	(Check all applicable)			
BIOGEN IDEC INC., 133 BOSTON POST ROAD	(Month/Day/Year) J 07/16/2013	_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
WESTON, MA 02493		Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac	quired, Disposed of, or Beneficially Owned			
(Instr. 3) any	emed 3. 4. Securities Acquired on Date, if Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) /Day/Year) (Instr. 8) (A) or	5. Amount of Securities6.7. Nature of IndirectBeneficiallyForm: DirectBeneficial OwnedOwned(D) orOwnershipFollowingIndirect (I)(Instr. 4)Reported(Instr. 4)Transaction(s) (Instr. 3 and 4)Indirect (I)			
Common Stock 07/16/2013	Code V Amount (D) Price $S(\underline{1})$ 2,239 D $\begin{array}{c}\$\\223.9\end{array}$	48 000 D			
Common Stock		5,378 I by Trust			
Common Stock		5,378 I by Trust			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: BIOGEN IDEC INC. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Under Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secut Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SCANGOS GEORGE A BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493	X		Chief Executive Officer			
Signatures						
Matthew S. Gilman, Attorney i Scangos	n Fact for	George A.	07/18/2013			
<u>**</u> Signature of Repor	ting Person		Date			

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.